| Patients N = 256 |
---|---|
Demographic characteristics | |
 Male sex | 143 (55.9) |
 Age (years), mean (SD) | 74.76 (10.59) |
Clinical characteristics | |
 AT9 Thromboembolic risk | |
  Low | 135 (52.7) |
  Moderate | 38 (14.8) |
  High | 40 (15.6) |
  Other VKA indication a | 33 (12.9) |
  Risk factors unknown | 10 (3.9) |
 Atrial fibrillation | 190 (74.2) |
 Mechanical heart valve | 20 (7.8) |
 Venous thromboembolism | 34 (13.3) |
 Previous thromboembolic event during VKA interruption | 3 (1.2) |
 iCVA/TIA | 37 (14.5) |
 Thrombophilia | 7 (2.7) |
 Coronary heart disease | 74 (28.9) |
 Heart failure | 20 (7.8) |
 Hypertension | 129 (50.4) |
 Diabetes mellitus | 62 (24.2) |
 Active cancer/malignancy | 54 (21.5) |
 Previous bleedingb | 13 (5.1) |
 VKA regimen | |
  Acenocoumarol | 203 (79.3) |
  Phenprocoumon | 53 (20.7) |
 Length of stay (days): median (IQR) | 6 (3–10) |
Surgery characteristics | |
 Elective | 181 (70.7) |
 Type of 1st surgery | |
  Urologic | 40 (15.6) |
  Orthopaedic | 89 (34.8) |
  Gastrointestinal | 52 (20.3) |
  Vascular | 36 (14.1) |
  Other | 39 (15.2) |
 Surgical bleeding risk | |
  High | 209 (81.6) |
  Moderate | 44 (17.2) |
  Low | 3 (1.2) |